

If patient progresses to death determination by neurologic criteria after this order set is implemented, the *Donation after* Death Determination by Neurologic Criteria Order Set (Adult) should be referenced for additional orders.

# Administrative

Section 1.1 Strative Ensure decision to withdraw life-sustaining measures (WLSM) is documented in the patient's chart								
Dr to consult/assume MRP								
Allergies or hypersensitivities?								
MRSA screening and clinical management protocol								
Monitoring								
⊠ Weight:kg □ actual □ estimate								
Height: cm actual estimate								
☑ Continuous cardiac/SpO₂ monitoring								
Heart rate, respiratory rate, blood pressure (arterial where possible) q1h and PRN								
☐ Intake and output q1h								
Core temperature (esophageal, rectal, bladder, central venous or arterial catheter) q4h and PRN								
U Tubes/Lines								
Naso/Orogastric Tube								
If not using for nutritional support, Nasogastric tube or Orogastric tube to straight drainage								
Urinary Catheter								
C Urinary catheter to urometer								
Arterial Line								
Insert arterial line for the purpose of determining death by circulatory criteria, as well as hemodynamic and arterial blood gas monitoring								
Interventions								
Warming blanket to maintain core temperature between 35.5 degrees Celsius and 37.0 degrees Celsius								
Apply Lacri-Lube <sup>®</sup> or alternative ophthalmic lubricant to both eyes q2-4h								
⊠ Turn patient q2h ⊠ Head of bed elevated at 35 – 45 degrees (as tolerated)								
Laboratory Investigations								
Initial Investigations								
Blood for Serology and Human Leukocyte Antigen (Consult with Ontario Health (Trillium Gift of Life Network) [TGLN])								
<ul> <li>Ontario Health (TGLN) will provide tubes and arrange specimen transport</li> </ul>								
Draw prior to fluid bolus and/or transfusion if possible								
Group+Screen (hardcopy result on chart)								
If blood group A or AB subtyping must be requested (Consult with Ontario Health [TGLN])								
⊠ Initial labs (as below) to be done q6h and PRN								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								
⊠ Initial labs (as below) to be done q6h and PRN								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								
<ul> <li>Initial labs (as below) to be done q6h and PRN</li> <li>Hematology and Coagulation</li> <li>☑ CBC</li> <li>☑ INR</li> </ul>								
⊠ Initial labs (as below) to be done q6h and PRN Hematology and Coagulation								

YYYY-MM-DD HH:MM

SIGNATURE

**Ontario Health** Trillium Gift of Life Network

Page **1** of **5** 1-Apr-2024

ID

PRINTED NAME

Submitted by:

Practitioner:



#### Laboratory Investigations Continued....

#### Chemistry

Electrolytes

Albumin Bilirubin (total and direct), ALT, AST, ALP, LDH, GGT, Lipase

Creatinine

e ⊠ Lactate ⊠ Magnesium, Calcium, Phosphate

### Toxicology

- \*\*\*Serum and urine toxicology screen for all patients unless possibility of overdose ruled out by MD or previously done\*\*\*
- Serum toxicology screen (if indicated by admission history or previous results)
- Urine toxicology screen

#### Supplemental Laboratory Investigations

Activated Partial Thromboplastin Clotting Time (aPTT) NOW and PRN

 $\boxtimes$  Protein (Total)  $\mathbf{NOW}$  and PRN

- $\boxtimes$  Amylase **NOW** and PRN
- Hemoglobin A1C NOW

Capillary blood glucose monitoring PRN and as per hospital policy/procedure

Blood Urea Nitrogen (BUN) NOW and PRN

 $\boxtimes$  Urinalysis  $\mathbf{NOW}$  and  $\mathsf{PRN}$ 

If patient known to have Type 1 or Type 2 diabetes-urine albumin to creatinine ratio NOW and PRN

□ If hospital is unable to perform urine albumin to creatinine ratio test AND patient known to have Type 1 or Type 2 diabetes-urine protein to creatinine ratio **NOW** and PRN

# Microbiology, Virology-Blood, urine and sputum cultures must be completed within 24 hours of organ donation consent as per Health Canada requirements.

Blood Culture and Sensitivity (C+S) (two different sites) NOW and PRN

Sputum C+S NOW and PRN (initial sample NOT required IF BAL C&S completed)

Urine C+S **NOW** and PRN (minimum of **ONE** urine culture is required by Health Canada for all potential organ donors, regardless of urinalysis results)

#### Additional Lab Orders

## Antibiotics/Antimicrobial Management

 $\boxtimes\mbox{Continue}$  current antibiotics for presumed or proven infection

## Hemodynamic Monitoring and Therapy Targets

Blood pressure indices:

- · Heart rate greater than or equal to 60 beats/minute and less than or equal to 120 beats/minute
- Systolic blood pressure (SBP) greater than or equal to 100 mmHg and less than or equal to 160 mmHg

· Mean arterial blood pressure (MAP) greater than or equal to 65 mmHg

Note: Maintain Hemoglobin greater than 70 g/L

 Submitted by:
 ID
 PRINTED NAME
 YYYY-MM-DD HH:MM

 Practitioner:
 ID
 PRINTED NAME
 YYYY-MM-DD HH:MM





#### **Cardiovascular Management**

\*\*\*Exact dosing for each medication to be calculated and individualized\*\*\*

Hypotension Management (Use Mean Arterial Pressure (MAP) unless arterial monitoring unavailable or unreliable)

 $\boxtimes$  IV Ringer's Lactate 500ml over 10 minutes PRN if SBP less than 100mmHg or MAP less than 65 mmHg

🖾 Vasopressin IV infusion at 0.1 – 2.4 units/h PRN for SBP less than 100 mmHg or MAP less than 65 mmHg

□ Norepinephrine IV infusion at 1 – 30 micrograms/minute PRN for SBP less than 100 mmHg or MAP less than 65 mmHg

Epinephrine IV infusion at 1 – 20 micrograms/minute PRN for SBP less than 100 mmHg or MAP less than 65 mmHg

#### Hypertension Management (Use MAP unless arterial monitoring unavailable or unreliable)

\*\*\*Wean inotropes or vasopressors if infusing; start antihypertensives for SBP above 160 mmHg and/or MAP above 90 mmHg\*\*\*

□ Hydralazine 10 – 20 mg IV q4h PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg

□ Nitroglycerin IV infusion at 5 – 200 micrograms/minute PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg

□ Labetalol IV infusion at 1 – 2 mg/min PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg (discontinue if HR below 65)

Esmolol \_\_\_\_\_micrograms/kg/min IV bolus (100 – 500 micrograms/kg IV bolus; consider reduced dose in the elderly population) followed by Esmolol 100 – 300 micrograms/kg/minute IV infusion PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg

#### **Mechanical Ventilation Targets**

- Tidal volume measurements: Tidal volume (Vt) 6 8 mL/kg
- PEEP: Positive End Expiratory Pressure 8-10 cm H<sub>2</sub>O
- PIP: Peak Inspiratory Pressure equal to or below 30 cm H<sub>2</sub>O

#### **Respiratory Management**

Chest x-ray q12h and PRN (coordinate to perform post-recruitment maneuver-see below)

🗌 Bronchoscopy and Bronchial Alveolar Lavage (BAL): Gram Stain and C+S x 3 (separate samples from each lung and 1 sample

for Ontario Health [TGLN] COVID requirements) and PRN (see Associated Ontario Health [TGLN] Document)

Routine ETT suctioning as tolerated q2h and PRN

Salbutamol 8 puffs q2 – 4h PRN for wheezing

☑ Ipratropium 8 puffs q2 – 4h PRN for wheezing

#### **Recruitment Maneuvers**

\*\*\*Target to maintain normalized arterial blood gases: pH 7.35 – 7.45, PaCO<sub>2</sub> 35 – 45 mmHg, PaO<sub>2</sub> equal to or above 80 mmHg, O<sub>2</sub> sat equal to or above 95%\*\*\*

□ For all potential lung donors: In the following sequence, perform recruitment maneuvers and challenge arterial blood gases (ABG) q6h and PRN (stop if lung donation excluded by Ontario Health [TGLN], recruitment manoeuvers not tolerated or as dictated by patient status)

Perform the following recruitment maneuvers in sequence:

- Pre-oxygenate with FiO2 of 1.0 for 10 minutes
- Sustained inflation with PEEP of 30 cm H<sub>2</sub>O for 30 seconds
- Maintain FiO<sub>2</sub> of 1.0 and return to maintenance ventilatory parameters
- Draw ABG 10 minutes post inflation (while FiO<sub>2</sub> at 1.0)
- Return to maintenance FiO<sub>2</sub> once complete
- Obtain chest x-ray once completed

☐ If lung recruitments not tolerated – ABG on Fi02 1.0 q6h and PRN

□ If lung donation excluded by Ontario Health (TGLN) – stop lung recruitment maneuvers and continue ABG and CXR as per unit protocols

Submitted by:	ID	PRINTED NAME	YYYY-MM-DD HH:MM	Read Back				
Practitioner:								
	ID	PRINTED NAME	YYYY-MM-DD HH:MM	SIGNATURE				

Page **3** of **5** 1-Apr-2024





## Fluid and Electrolyte Targets

- Urine output 0.5 3 mL/kg/h (if urine outputs below 0.5 cc/hr OR urine output above 300cc/hr consult MRP)
- Serum sodium equal to or above 130 mmol/L and equal to or below 150 mmol/L
- Normal ranges for potassium, calcium, magnesium and phosphate
- Blood glucose 6 10 mmol/L

## Fluid and Electrolytes

\*\*\*Exact dosing for each medication to be calculated and individualized\*\*\*

Ringers Lactate IV infusion for maintenance at

If serum sodium above 145 mmol/L evaluate for Diabetes Insipidus

Implement hospital standing order set for electrolyte imbalances **OR** follow below:

□ If serum phosphate below 0.65 mmol/L, then administer sodium phosphate 15 mmol in 100 mL D5W IV as per unit protocol

mL/h

□ If corrected serum calcium below 2.0 mmol/L or ionized calcium below 1.0 mmol/L, then administer 10% calcium gluconate 1 gram in 100 mL NaCl or D5W IV over 30 minutes (central or peripheral)

☐ If serum magnesium below 0.8 mmol/L, then administer magnesium sulphate 1 g in 50 – 100 mL NaCl or D5W IV over 30 minutes (central or peripheral)

☐ If serum potassium below 3.9 mmol/L and above 3.2 mmol/L, then administer 20 mmol KCl in 50 – 100 mL NaCl or D5W via central line over 1 hour

□ If serum potassium below 3.2 mmol/L, then administer 40 mmol potassium chloride in 100 mL NaCl or D5W via central line over 2 hours

\*\*\*DO NOT ADMINISTER HYDROXYETHYL STARCH e.g. VOLUVEN\*\*\*

#### **Glycemic and Nutrition Management**

Initiate or continue nutritional support, when appropriate and possible-all nutritional support to be stopped 6 hours prior to planned WLSM

Initiate and titrate insulin infusion to maintain serum glucose 6 – 10 mmol/L

# **Endocrine and Metabolic Management**

\*\*\*Exact dosing for each medication to be calculated and individualized\*\*\*

⊠ For all potential lung donors – methylprednisolone 15 mg/kg (maximum 1g) IV q24h (Stop if lung donation excluded by Ontario Health [TGLN])

If lung donation excluded by Ontario Health (TGLN) <u>AND</u> patient requiring vasopressors then administer hydrocortisone 50 mg IV g6h

Initiate or continue hospital insulin infusion order set to maintain serum glucose 6-10 mmol/L

☑ If creatinine clearance below 60 mL/min, kidneys have NOT been ruled out for transplant and IV contrast is planned, give IV 0.9% NaCl 3 mL/kg/h for 3 hours pre-contrast then 1 mL/kg/h for 6 hours post-contrast

Submitted by:				Read Back	
Submitted by.	ID	PRINTED NAME	YYYY-MM-DD HH:MM		
Practitioner:					
	ID	PRINTED NAME	YYYY-MM-DD HH:MM	SIGNATURE	
Page <b>4</b> of	5				
1-Apr-202				57	Ontario Health
					Trillium Gift of Life Network



#### References

- Ball, I.M., Hornby, L., Rochwerg, B., Weiss, M.J., Gillrie, C., Chassé, M., et al. (2020). Management of the neurologically deceased organ donor: A Canadian clinical practice guideline. CMAJ, April 06, 2020 192 (14) E361-E369; DOI: https://doi.org/10.1503/cmaj.190631
- Canadian Council for Donation and Transplantation. (2004). Medical management to optimize donor organ potential: A Canadian forum: Report and recommendations. February 23-25, 2004, Mont Tremblant, P.Q.
- Frontera, J.A., & Kalb, T. (2010). How I manage the adult potential organ donor: donation after neurological death (Part 1). *Neurocritical Care*, 12, 103-110.
- Mascia, L., Pasero, D., Slutsky, A.S., Arguis, M., J., Berardino, M., Grasso, S., et al. (2010). Effect of lung protective strategy for organ donors on eligibility and availability of lungs for transplant. *Journal of the American Medical Association*, 304(23), 2620-2627.
- Nice Sugar Study Investigators. (2009). Intensive versus conventional glucose control in critically ill patients. *The New England Journal of Medicine*, 360 (13), 1283-1297.

